A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.
Latest Information Update: 24 May 2016
Price :
$35 *
At a glance
- Drugs Orantinib (Primary) ; Gimeracil/oteracil/tegafur; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 05 Feb 2013 New trial record
- 26 Jan 2013 Primary endpoint 'Progression-free-survival-duration' has not been met.
- 26 Jan 2013 Results presented at the 2013 Gastrointestinal Cancers Symposium.